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Hyaluronan is activated by fragmentation and con-
trols inflammation and fibroplasia during wound re-
pair and diseases (eg, cancer). Hyaluronan-binding
peptides were identified that modify fibrogenesis dur-
ing skin wound repair. Peptides were selected from 7-
to 15mer phage display libraries by panning with
hyaluronan-Sepharose beads and assayed for their
ability to block fibroblast migration in response to
hyaluronan oligosaccharides (10 kDa). A 15mer pep-
tide (P15-1), with homology to receptor for hyaluro-
nan mediated motility (RHAMM) hyaluronan binding
sequences, was the most effective inhibitor. P15-1
bound to 10-kDa hyaluronan with an affinity of Kd 
107 and appeared to specifically mimic RHAMM since it
1250significantly reduced binding of hyaluronan oligosaccha-
rides to recombinant RHAMM but not to recombinant
CD44or TLR2,4, and alteredwound repair inwild-type but
not RHAMM/mice. One topical application of P15-1 to
full-thickness excisional rat wounds significantly reduced
wound macrophage number, fibroblast number, and
blood vessel density compared to scrambled, negative
control peptides. Wound collagen 1, transforming growth
factor -1, and -smooth muscle actin were reduced,
whereas tenascin C was increased, suggesting that P15-1
promoted a form of scarless healing. Signaling/microar-
ray analyses showed that P15-1 blocks RHAMM-regulated
focal adhesion kinase pathways in fibroblasts. These re-
sults identify a new class of reagents that attenuate proin-
flammatory, fibrotic repair by blocking hyaluronan oligo-
saccharide signaling. (Am J Pathol 2012, 181:1250–1270;
http://dx.doi.org/10.1016/j.ajpath.2012.06.036)
Hyaluronan (HA) is a key extracellular matrix regulator of
innate immune processes, fibroblast functions, and cell
migration during normal response to injury.1–8 During
wound repair, HA synthesis is required for mesenchymal
differentiation, including transforming growth factor -1
(TGF1)-mediated differentiation of myofibroblasts, col-
lagen production by dermal fibroblasts, and endothelial
cell proliferation and migration.9–13 Wound HA is also a
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tissue repair and dendritic cell function that link adaptive
immunity to innate immune responses during repair. The
effects of HA on these aspects of wound healing depend
on its molecular weight. For example, native high molec-
ular weight HA (eg, 500 kDa) reduces inflamma-
tion3,14–17 and angiogenesis, and during skin excisional
wound repair, increases the expression of transforming
growth factor  (TGF3), metalloproteinase 1 and 3
(MMP1, -3), and collagen III (Col3A1) in human dermal
fibroblasts.18–20 By contrast, fragmented HA that is pres-
ent in intermediate sizes (50 to 400 kDa), and as smaller
oligosaccharides (20 kDa), promotes inflammation, an-
giogenesis, and migration of most cell types involved in
tissue repair. HA fragments also strongly promote ex-
pression of collagen I (Col1A1), tissue inhibitor of metal-
loproteinase 1 (TIMP1), and TGF1.21–28 The biological
differences of native HA versus fragments are due in part
to their ability to activate specific signaling cascades
through HA receptors such as CD44 (cluster designation
44), receptor for hyaluronan mediated motility (RHAMM;
human form, HMMR) and Toll-like receptors 2 and 4
(TLR-2, -4). For example, HA fragment:HA receptor inter-
actions activate AP-1 and NFB-regulated signaling cas-
cades, which culminate in the expression of genes that
enhance inflammation and angiogenesis, and promote
cell migration.4,29,30 Specific blockade of these HA frag-
ments could have significant therapeutic potential for
treating diseases that result from chronically high levels
of proinflammatory cytokines and consequent elevation
in angiogenesis and cell migration. To date, pathologies
involving HA fragmentation include inflammatory bowel
disease,31 arthritis,8,32 disorders leading to chronic fibro-
sis (eg, lung), and cancers, such as bladder, prostate,
and breast cancer in which HA accumulation/fragmenta-
tion is associated with poor prognosis.1,2,33
HA-binding peptides that can interfere with the biolog-
ical functions of HA have previously been designed and
demonstrated to modify tissue fibrosis, wound infection,
contact hypersensitivity, and melanoma metastases in
experimental models providing proof of concept34–37 for
the use of peptides to influence HA-driven disease pro-
cesses. However, their mechanism of action is still not
understood since both binding affinity to HA and se-
quence homology to known HA receptors are low (25%,
eg, Mummert et al38).
Previous studies in our laboratory using RHAMM-null
mice demonstrated an involvement of this HA receptor in
the healing of excisional dermal wounds.39 In particular,
RHAMM loss blunted fibrotic repair, reduced white cell
migration into wounds, and reduced myofibroblast differ-
entiation. This study suggested that blocking RHAMM/HA
interactions could have therapeutic benefits in repair and
disease processes. In the present study, our goal was to
develop synthetic peptides that mimic specific structural
motifs found within RHAMM that are required for binding
to HA and that block HA fragmentation–driven events
during excisional skin wound repair, in particular inflam-
mation and fibrogenesis. Toward this end 7-, 12-, and
15mer phage display libraries were panned with HA frag-
ments/oligosaccharides linked to Sepharose beads. Thisapproach led to the identification of a 15mer peptide
(P15-1) that is highly homologous to the HA binding se-
quence of RHAMM. P15-1 preferentially binds HA oligo-
saccharides (10 kDa) with a moderate affinity (kDa 
107 mol/L). Here, we show that this peptide specifically
mimics and blocks RHAMM:HA signaling through focal
adhesion kinase (FAK), resulting in the modification of
wound healing responses in wild-type (eg, RHAMM/)
but not RHAMM/ wounds. We interpret our results to
suggest that interference with RHAMM/HA fragment in-
teractions reduces fibrogenesis and scar formation, both
as a result of blunting the proinflammatory functions of
macrophage subpopulations and by directly modifying
specific mesenchymal properties of wound cells such as
myofibroblast differentiation via blocking key signaling
pathways.
Materials and Methods
Materials
Chemoenzymatically synthesized HA standards of low
polydispersity and known molecular mass based on size
exclusion chromatography with multiangle light scattering
(Select-HA: standard mixtures HiLadder and LoLadder), as
well as streptavidin-based assemblies of one to four bi-
otin–end-labeled HA molecules (Mega-HA) were ob-
tained from Hyalose LLC (Oklahoma City, OK) for use in
agarose gel electrophoresis analyses.40 HA used for
screening random phage libraries, isothermal titration
calorimetry (ITC), enzyme-linked immunosorbent assay
(ELISA) binding studies, and scratch wound–induced
cell migration experiments had an average molecular
weight of 240 kDa and was the kind gift of Hyal Pharma-
ceutical Corp (Mississauga, ON, Canada). Higher molec-
ular weight HA used for ITC (500 kDa) was also the kind
gift of Hyal Pharmaceutical Corp. HA oligosaccharides
were prepared by partially digesting hyaluronidase with
Streptococcus to generate a heterogeneous mixture of
HA fragments [Oligo HA, average molecular weight
(MWav): 10 kDa].
40 Purified HA oligosaccharides of spe-
cific sizes that were used for stimulating cell migration
were the kind gift of Seikagaku Corp. (Tokyo, Japan). All
HA preparations were free of protein or nucleic acid
contamination, as determined by gel electrophoresis fol-
lowed by Coomassie Blue and ethidium bromide stain-
ing, respectively, and free of endotoxin as determined by
an endotoxin assay (endotoxin assay kit; GenScript, Pis-
cataway, NJ). Chondroitin 4/6 sulfate was purchased from
Sigma (St. Louis, MO). Agarose (agarose NA, mr  0.10)
was obtained from GE Healthcare (Little Chalfont, UK).
Pierce Strong Anion Exchangemini spin columns and Slide-
A-Lyzer mini dialysis units with a 10,000 molecular-weight
cutoff were obtained from Thermo Scientific (Waltham, MA).
Stains-All dye (3, 3=-dimethyl-9-methyl-4, 5, 4=, 5=-diben-
zothiacarbocyanine) and bromophenol blue tracking dye
were obtained from Bio-Rad Laboratories (Hercules, CA).
All other chemicals were reagent grade quality, and all
water was deionized. Antibodies (Ab) used were rabbit
anti-rat collagen I (Biodesign International, Saco, ME),
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macrophage-3 antigen (MAC-3) (Pharmingen/BD Biosci-
ences, San Jose, CA), arginase 1 (ARG1) (Sigma), induc-
ible nitric oxide synthase (iNOS) (AbCam, Cambridge,
UK), tenascin C (Dako, Glostrup, Denmark), smooth
muscle actin (Sigma), and TGF1 (AbCam). Polymerase
chain reaction (PCR) oligonucleotides were purchased
from Sigma Genosys (Sigma). ELISA kit for quantification
of HA, EZ-Link Sulfo-NHS-Biotinylation kit, and SYBER
Green real-time PCR reagents were purchased from Ech-
elon Biosciences (Salt Lake City, UT), Pierce Biotechnol-
ogy (Fisher Scientific, Ottawa, ON, Canada), and Bio-
Rad, respectively, and were used according to the
manufacturers’ instructions. Streptavidin/alkaline phos-
phatase for ELISA was purchased from Dako. Cell lines:
RHAMM-overexpressing (LR21) cells, RH/, RhFl-res-
cued, and CD44/ cells were prepared as previously
described.39 Rat dermal fibroblasts were purchased from
the ATCC # CRL-1213 (ATCC, Manassas, VA).
Isolation of HA-Binding Clones from
Recombinant Phage Display Libraries
The 15mer phage display library was a kind gift of Chiron
(Emeryville, CA) and had a complexity of approximately
1  1013 transformants. The 12mer library was pur-
chased from New England BioLabs (M13 phage library,
Ph.D.-12 kit; New England BioLabs, Ipswich, MA) and
contained an estimated complexity of 1.2  109 transfor-
mants. The 7mer library (Ph.D.-7) was also purchased
from New England BioLabs and contained a complexity
of 2.8  109 transformants. Sequences from both the 7-
and 12mer libraries were fused to gene 3 (pIII) proteins.
The funnel for identifying HA-binding sequences from
each phage display library is summarized in Supplemen-
tal Figure S1 (available at http://ajp.amjpathol.org). HA
fragments (MWav  200 kDa) were linked to Sepharose
beads as previously described41 and incubated in phos-
phate-buffered saline (PBS) with each of the phage librar-
ies at 4°C overnight on a shaker. Beads were recovered
by centrifugation and washed four times in PBS (pH 7.4).
Phage were released by incubating HA-Sepharose
beads with 10 mg/mL HA (MWav  200 kDa). The recov-
ered phage were grown on an Escherichia coli bacterial
lawn in Petri dishes for amplification and then subjected
to three additional rounds of positive selection for binding
to HA-Sepharose and amplification in E. coli. HA binding
phage were then incubated with chondroitin sulfate (CS)-
Sepharose and bound phage were discarded. The re-
maining phage were grown on a bacterial lawn, 75
independent phage plaques were picked from the
screen of each library, and these were sequenced in
an automated DNA sequencer. Sequences were
aligned with each other and also with RHAMM (mouse,
accession number: NP_038580.2), CD44 (mouse, ac-
cession number: CAJ18532.1), Toll-like receptor 2
(TLR2; mouse, accession number: NP_036035.3), and
Toll-like receptor 4 (TLR4; mouse, accession number:
NP_067272.1) using Cobalt Multiple Alignment Tool (Co-
balt Constraint-based Multiple Protein Alignment Toolwebsite, http://www.ncbi.nlm.nih.gov/tools/cobalt, last ac-
cessed March 12, 2012).
HA Pull-Down Assays
AH Sepharose 4B (0.5 g) was resuspended in 0.5 mol/L
NaCl. The Sepharose gel was washed 3 with water (pH
4.5) to remove NaCl, and resuspended in 1 mL of water
(pH 4.6). HA (10 kDa, 1 mg/mL) was added to the gel in
a ratio of 2:1 (volume/volume) and incubated for 30 min-
utes at room temperature. Solid carbodiimide (EDC) pow-
der was added to a final concentration of 0.1 mol/L. The
pH was maintained at 4.5 to 5.5 for 1 hour (by addition of
diluted NaOH). After 1 hour, changes observed in pH
were small. The reaction was allowed to proceed for 24
hours at 4°C. The gel was washed thoroughly with water
5 (pH 4.5) and was then equilibrated with 1 PBS
buffer (pH 7.6).
RHAMM-overexpressing fibroblasts were pelleted and
lysed with 1 mL of radioimmunoprecipitation assay buffer
[containing phenylmethanesulfonyl fluoride, 0.0002 mol/L
final concentration, and Calbiochem protease inhibitors,
0.1% final concentration (Millipore, Billerica, MA)], incu-
bated for 1 hour on ice, followed by sonication (3  10
seconds, with 50% pulse). The lysate was centrifuged at
13,000  g for 15 minutes, and the supernatant fraction
(protein concentration was 4 mg/mL) was used for pull-
down assay.
A total of 100 L of HA-coupled AH Sepharose beads,
ratio 1:1, was mixed with 100 L of cell lysate and incu-
bated overnight at 4°C. The beads were centrifuged at
13,000 g for 5 minutes and washed three times with 1
PBS (pH 7.6). The supernatant was discarded, and pro-
teins were eluted from Sepharose beads with 50 L of 1
sample buffer at 9°C during 10 minutes. The gel was
centrifuged, and supernatant fractions were analyzed by
Western blot analysis. For detection of RHAMM in pull-
down samples, anti-RHAMM Ab (rabbit monoclonal,
Epitomics CD 168/RHAMM; Epitomics, Burlingame, CA)
was used at a dilution of 1:1000 and secondary anti-
rabbit Ab at a dilution of 1:10,000. The reaction was
detected by enhanced chemiluminescence.
Synthesis and Labeling of Peptides
Peptides were synthesized, purified using preparative
high-performance liquid chromatography, and then char-
acterized by electrospray ionization (ESI) mass spec-
trometry. Scrambled peptides were prepared by synthe-
sizing random sequences of the exact amino acid
composition of sense peptides. Biotinylated peptides
were prepared by synthesizing peptides with an addi-
tional cysteine residue at the COOH terminus and then
covalently linking biotin to this residue.
In Vitro Scratch Wound Assays
Function blocking anti-RHAMM peptide Ab were pre-
pared against sequence encoded in the N-terminus of
murine RHAMM (ProSci, San Diego, CA42). Cells were
plated at 7  105 cells/well in six-well plates using Dul-
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Invitrogen, Carlsbad, CA) containing 10% fetal calf serum
(FCS). Confluence of cell monolayers after 24 hours was
between 80% and 90%. Cells were injured with either a
2-mm single-edge scraper [RHAMM-overexpressing
(LR21) cells, Rh/, Rh-rescued, and CD44/ mouse
embryonic fibroblasts (MEF)] or a yellow pipette tip (rat
dermal fibroblasts) producing one injury/well.39 Cells
were washed twice with PBS and incubated for 10 to 12
hours with medium containing 30 g/mL peptides or 30
g/mL anti-RHAMM blocking Ab unless otherwise indi-
cated. For quantification of HA fragment–stimulated (eg,
200 kDa) or oligosaccharide-stimulated (eg, low polydis-
persity, 6-kDa 30mer or more, polydisperse mixture av-
eraging 10 kDa) cell migration, culture medium was
changed to DMEM plus 1% FCS, and 50 ng/mL HA
fragments/oligosaccharides were added. To block HA
fragment/oligosaccharide-stimulated cell migration, 30
g/mL peptides were added concomitantly with HA. Cell
cultures were incubated for 24 hours at 37°C and 5%
CO2. Following incubation, cells were stained with hema-
toxylin, and images were taken using a 5 modulation
objective (Carl Zeiss, Oberkochen, Germany) attached to
a Zeiss Axiovert 100 inverted microscope equipped with
Hoffman Modulation contrast optical filters (Modulation
Optics, Greenvale, NY). The number of cells that mi-
grated into the scratch wound was counted using 70%
of the width of the scratch wound. Statistically signifi-
cant (P  0.05) differences were assessed by the
unpaired Student’s t-test method using Microsoft Excel
software (Redmond, WA).
Preparation of Recombinant RHAMM, CD44,
and TLR4 Proteins
Recombinant human CD44 was purchased from Origene
(Rockville, MD), and human TLR2 and -4 recombinant pro-
teins were purchased from Abnova (Taipei, Taiwan). Mouse
recombinant glutathione S-transferase (GST) RHAMM pro-
tein was prepared as previously described.42 Recombinant
protein RHAMM-COOH terminus (amino acids 706 to 766,
sequence: RDSYAQLLGHQNLKQKIKHVVKLKDENSQLK-
SEVSKLRSQ LVKRKQNELR LQGELDKALG I, molecular
weight  7.1 kDa, pI  10.1) was isolated from E. coli
BL21 (D3) strain carrying the recombinant plasmid
pPAL7-RHAMM. Bacteria were grown overnight at 37°C
in liquid broth medium containing ampicillin (100 g/mL)
and 0.5% glucose, and allowed to grow to mid-log phase.
Recombinant RHAMM gene expression was induced
with 2 mmol/L isopropyl -D-1-thiogalactopyranoside for
4 hours at 37°C, and bacterial cells were harvested by
centrifugation at 10,000  g for 20 minutes. Bacterial
cells were re-suspended in lysis buffer [composed of 0.2
mol/L sodium phosphate, 0.2 mol/L potassium acetate,
1% triton X-100, and 0.1% protease inhibitors (pH 7.0)],
sonicated (60 seconds, 10 seconds/pulse), and centri-
fuged (4°C, 12,000  g, 20 minutes). The resulting su-
pernatant was transferred to a clean tube and filtered
(using a 0.45-m filter). Purification of the eXact-tagged-
recombinant RHAMM was conducted with Profinity eXact(Bio-Rad) affinity resin according to the manufacturer’s
protocol. For these experiments, the lysate was loaded in
a gravity column packed with Profinity eXact affinity resin
(4 mL of resin, column 15  1.5 cm) equilibrated with
wash buffer [0.2 mol/L sodium phosphate (pH  7.0)].
The column was washed with wash buffer to eliminate
impurities, and recombinant RHAMM was eluted with elu-
tion buffer [composed of 0.2 mol/L sodium phosphate,
0.1 mol/L sodium fluoride (pH  7.0)]. The protein was
then dialyzed and concentrated, using a Millipore filter
(cutoff: 3 kDa) in a buffer consisting of 0.2 mol/L sodium
phosphate and 0.2 mol/L potassium acetate (pH 7.0).
The purity of the isolated protein was verified on one-
dimensional sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Identification of RHAMM
was performed and confirmed with anti-RHAMM Ab by
Western blot analysis. The purity of recombinant RHAMM
was assessed by high-performance liquid chromatogra-
phy and mass spectrometry analysis (electrospray ion-
ization) of the molecular weight. Purity ranged from 80%
to 90%, and the major contaminant was GST. Therefore,
GST alone was used in binding assays as a negative
control for GST-RHAMM.
Binding of Peptide 15-1 to HA in an ELISA
ELISA plates (Nalge Nunc, Penfield, NY) were coated
overnight with 20 g of HA oligosaccharides/well, pre-
pared as a testicular hyaluronidase digestion, and result-
ing in an MWav  10 kDa (see above) or purified 4mer to
50mer HA oligosaccharides (kind gift of Seikagaku).
Negative control wells were incubated with PBS. Excess
HA was removed by washing with PBS three times for 5
minutes. Nonspecific binding sites were covered by in-
cubation of the ELISA plate with 3% bovine serum albu-
min/PBS for 1 hour at room temperature followed by three
5-minute PBS washes. For biotinylation of peptides, a
commercially available biotinylation kit43 was used. A
total of 10 mL of peptide solution (2 g/mL in PBS) was
mixed with 10 mmol/L Sulfo-NHS-Biotin (Fisher Scientific)
and incubated for 3 hours at room temperature. Excess
biotin was removed by passage over a gel filtration col-
umn. The biotinylated peptide was diluted 1:3 and added
to the HA-coated ELISA plates (100 L of biotinylated
peptide/well) followed by a 1-hour incubation at room
temperature and three 5-minute wash steps with PBS.
HA-coated positive control wells were incubated with
1:50 diluted biotinylated HA detection probe from Eche-
lon Biosciences. For detection of biotinylated peptides
that were bound to HA, ELISA plates were incubated with
a 1:1000 dilution (100 L/well) of streptavidin-phospha-
tase (Dako) for 1 hour at room temperature followed by
three 5-minute PBS washes. Next, 100 L/well of 3,3-
diaminobenzidine (DAB)/buffer mixture were added, and
the plates were incubated for 10 minutes at room tem-
perature in the dark or until a color reaction was visible.
The light absorption was then measured with a Bio-Rad
3550 plate reader at 405 nm.
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A buffer solution of 0.9 mmol/L HA (MWav  10 kDa, in
disaccharide units molecular weight 401 g/mol) was in-
jected into a 0.6 mmol/L peptide 15-1 solution in 1 mol/L
2-(N-morpholino)ethanesulfonic acid (pH 6.0) at 25°C.
Experimental conditions: 28  10 L injections, 300 to
400 seconds of spacing, 1.0062  g, 60 seconds as an
initial delay, 10 mcal/second as the reference power.44
Excisional Skin Wounds
All animal experiments followed the guidelines of the
local animal use committee (University of Western On-
tario protocol #2009–60). Three-month-old Sprague
Dawley rats (female) were anesthetized and wounded by
lifting the back skin from the underlying muscle, pinching
the left and right sides of the skin together as one sheet
then placing punch biopsies through both sides at once
to generate two excisional wounds with each biopsy
punch. Three 4-mm of such punch biopsies resulted in 6
separate wounds in rats. The wounds were filled with 100
L of a sterile solution of 1% collagen type 1 gel (pH 7.2)
containing either PBS, HA-binding peptides, or scram-
bled peptide, which contained the same amino acids as
the HA-binding peptides but in a random order. After
application of the 1% collagen solutions to the wounds,
the collagen was allowed to gel for 20 minutes. At various
time points after wounding, the wounds were recovered
from the euthanized rats with an 8-mm punch biopsy.
Three- to six-month-old wild-type and RHAMM/ mice
were wounded as described for rats, with the exception
that only one full-thickness punch biopsy/mouse was
used, resulting in two wounds/mouse. Peptide treatment
and wound isolation were done as described for rats.
Quantification of Wound Contraction
Wound edges were traced at different times after wound-
ing using a transparent plastic sheet. Wound traces were
then scanned in, and the wound area45,46 was deter-
mined by image analysis using Image J software (NIH,
Bethesda, MD, http://rsb.info.nih.gov/ij, last accessed
April 22, 2010).
Cytokine Array
Rats were wounded as described above. Twenty-four
hours after wounding, wounds were removed and placed
on six-well cell culture plates in DMEM plus 10% FBS plus
antibiotic and antimycotic agents.47 P15-1 or scrambled
control peptide was added to the cultures (50 g/mL). At
days 3 and 7, culture medium was removed, and cyto-
kine profile was determined using Proteome Profiler Rat
Cytokine Array Panel A array kit (R&D Systems, Minne-
apolis, MN) following manufacturer’s instructions.Isolation and Purification of HA from Skin
Excisional Wounds
Skin samples, 60 to 100 mg, were digested overnight at
55°C in 500 L of 0.15 mol/L Tris, 0.15 mol/L NaCl, 0.01
mol/L CaCl2, 5 mmol/L deferoxamine mesylate (pH 8.3), 7
U of proteinase K/mg tissue, 0.1% SDS, followed by cen-
trifugation at 18,000  g for 5 minutes. Dry NaCl was
added to the supernatant to increase salt concentration
to 2 mol/L. An equal volume of chloroform was added,
and the samples were mixed by shaking. Samples were
spun at 18,000  g for 10 minutes. The upper, aqueous
phase was removed and dialyzed to 0.1 mol/L NaCl for 2
hours using MINI Dialysis Units 7000 MWCO (Thermo
Scientific). Samples were mixed with four volumes of
ethanol and stored overnight at 20°C. Samples were
spun at 18,000  g for 20 minutes at 4°C. Pellets were
dissolved in 100 L of 50 mmol/L Tris (pH 8), 20 mmol/L
NaCl plus 50 U of Benzonase followed by 4 hours incu-
bation at 37°C. NaCl concentration was increased to 2
mol/L, and samples were extracted with one volume of
chloroform. Aqueous and organic phases were sepa-
rated by 5 minutes of centrifugation, and the aqueous
phase was dialyzed against 0.1 mol/L NaCl for 2 hours.
HA was precipitated with four volumes of ethanol at
20°C overnight followed by 30 minutes of centrifugation
at 18,000 g and 4°C. Control samples were redissolved
in 30 L of water. Peptide-treated samples were redis-
solved in 100 L of water, boiled 5 minutes, and then
retreated with Benzonase, chloroform extraction, and
precipitation with ethanol before being dissolved in 30 L
of water. Crude HA was further purified by anion ex-
change chromatography. Each HA sample was dis-
solved in 20 L of water and then mixed with additional
water and 2 mol/L NaCl to reach a final volume of 400 L
in 0.1 mol/L NaCl. The entire sample was loaded on a
prewashed anion exchange mini spin column, and spun
at 2000  g for 5 minutes. The column was washed with
400 L of 0.1 mol/L NaCl. Three protocols were used in
elution of the HA from the column. Protocol 1 used for the
day 0 control sample: the column was eluted twice with
400-L aliquots of 0.7 mol/L NaCl. Protocol 2 used for
peptide-treated samples: the column was eluted twice
with 400-L aliquots of 0.4 mol/L NaCl, then twice with
400-L aliquots of 0.7 mol/L NaCl. In protocol 2, some
non-HA contaminants and some very low molecular mass
HA were eluted with the 0.4 mol/L NaCl, and then larger
HA was eluted with 0.7 mol/L NaCl. Protocol 3 used for
days 5 and 7 control samples: the anion exchange col-
umn was first eluted with 0.2 mol/L NaCl to remove some
non-HA contaminants, but no HA, and then eluted with
0.7 mol/L NaCl as for the day 0 sample. (Protocol 3 was
developed during the course of this study, and will be the
preferred protocol for the future.) Following each elution
protocol, the HA-containing eluate was dialyzed over-
night against water, and then dried using a centrifugal
vacuum concentrator. Quantitative analysis of the densi-
tometric data from electrophoretic analysis was per-
formed as has been described.48 The area under the
densitometric profile for each sample was calculated and
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HA had been isolated.
Agarose Gel Electrophoresis
The agarose gel electrophoresis method used in this
study was based on the method of Lee and Cowman,49
as adapted to a mini-gel format and optimized by Cow-
man and colleagues.50 Agarose gels (0.5% w/v) were
prepared in Tris/borate/EDTA buffer [100 mmol/L Tris-
borate, 1 mmol/L EDTA (pH 8.3)]. Approximately, 3.2 g
of HA isolated from each skin sample was purified by ion
exchange chromatography as described above, then
each fraction dissolved in 15 L of deionized water. A
3-L aliquot of loading buffer (0.02% bromophenol blue,
2 mol/L sucrose in 1 Tris/borate/EDTA) was added to
each sample. Select-HA standards were prepared in wa-
ter and loaded at 0.05 to 0.2 g per HA component. Gels
were pre-electrophoresed for 20 minutes at 40 V, and
then loaded and electrophoresed at 40 V for 3.5 hours.
The gel was stained overnight in 0.005% Stains-All in
50% ethanol, then destained in 10% ethanol solution. The
gel was scanned using a GE Healthcare ImageScanner
III running LabScan v.6. Quantitative analysis of the cal-
ibrated image was accomplished using ImageQuant TL
software.
RNA Extraction from Wounds
Punch rat skin biopsies were homogenized for 1 minute in
1 mL of Trizol, and total RNA was extracted by using
Trizol Reagent kit (Gibco BRL). The amount of total RNA
concentration was measured with a NanoDrop ND 1000
spectrophotometer (Thermo Scientific).
PCR
PCR amplification was performed using Platinum
TaqDNA polymerase (Gibco BRL) and specific primers
for -actin, collagen I, collagen III, ED-1, and regulated
on activation normal T cell expressed and secreted
(RANTES). PCR conditions were as follows: -actin.
Primer 1: 5=-CTCTTTGATGTCACGCACGATTTC-3=,
primer 2: 5=-GTGGGCCGCTCTAGGCACCAA-3=; 45
seconds at 94°C, 45 seconds at 60°C, 45 seconds at
72°C, 25 cycles. Collagen I. Primer 1: 5=-CGATGTCGC-
TATCCAGCTGA-3=, primer 2: 5=-AGTCCGAATTCCTG-
GTCTGG-3=; 45 seconds at 94°C, 45 seconds at 60°C,
45 seconds at 70°C, 20 cycles. Collagen III. Primer 1:
5=-GGGACACTCGGGAGAGATAC-3=, primer 2: 5=-AA-
CAATCAGTCAGCCATCTAC-3=; 45 seconds at 94°C,
45 seconds at 50°C, 45 seconds at 72°C, 25 cycles.
ED-1. Primer 1: 5=-CGATGGCAGGACAGTAGTCGC-3=,
primer 2: 5=-AAGGCTGCTGTTGAAAGGACG-3=; 45
seconds at 94°C, 45 seconds at 59°C, 45 seconds at
72°C, 29 cycles. RANTES. Primer 1: 5=-AAGATCTCTG-
CAGCTGCATC-3=, primer 2: 5=-ACACTTGGCGGTTC-
CTTCGA-3=; 45 seconds at 94°C, 45 seconds at 59°C,
45 seconds at 72°C, 29 cycles.RT-PCR
For the synthesis of oligo-dT–primed cDNA, 2 g of total
RNA, 1 g of oligo dT,28 and Moloney Murine Leukemia
Virus Reverse Transcriptase (Gibco BRL) or SuperScript
II Reverse Transcriptase (Invitrogen) were used. Follow-
ing 1-hour incubation at 37°C, the reaction was stopped
by heating at 95°C for 5 minutes, and 2 L of room
temperature reaction mixture was used for each PCR
reaction. PCR amplification was performed using a SY-
BER Green real-time PCR kit (Bio-Rad) following the man-
ufacturer’s instructions with the modification that the PCR
reaction was downscaled to 25 L.
Immunohistochemistry
Rat and mouse wounds were collected using an 8-mm
punch biopsy, and recovered punch biopsies were fixed
in freshly prepared 3.5% paraformaldehyde and pro-
cessed for serial paraffin sections. Five-micron sections
were obtained and deparaffinized by passage through
an alcohol series. Sections were stained with Masson’s
trichrome by the pathology department at the Hospital for
Sick Children in Toronto. Sections were stained for
MAC-3, TGF1, tenascin, smooth muscle actin, ARG1,
and iNOS using UltraVision LP detection system (Thermo
Scientific).
Quantification of Immunohistochemistry
Masson’s trichrome, tenascin C, and collagen I and -III
stained tissue section images were taken with air objec-
tives (4, NA 0.16;20, NA 0.7; Olympus, Tokyo, Japan)
on a microscope (AX70 Provis; Olympus) with a color
camera (Cooke SensiCam CCD imaging; PCO-TECH,
Romulus, MI) and Image-Pro Plus 4.5.1.2.9 (Media Cy-
bernetics, Rockville, MD). Image J software was used for
staining quantification. Color deconvolution plugin
DAB-HE was used to separate blue and brown pixels.
After application of the threshold function, positive pixels
were counted.
Wound Hydroxyproline Content
Weighed granulation tissue was hydrolyzed in 6 N HCl for
24 hours at 110°C, evaporated to dryness at 110°C, and
then dissolved in acetate buffer (pH 6) (25 g citric acid, 6
mL of glacial acetic acid, 60 g of sodium acetate 3H2O,
17 mg of sodium hydroxide to 500 mL of ddH2O) to 0.05
mg/mL. Two microliters of the sample was added to 98
L of acetate buffer (pH 6). One milliliter of chloramine
solution (1.4 g Chloramine-T, 10 mL of n-propanol, 10 mL
of ddH2O, 80 mL of acetate buffer) was added to each
tube and mixed. Tubes were incubated at room temper-
ature for 20 minutes. One microliter of Ehrlich solution (15
g of Ehrlich, 62 mL of n-propanol, 25 mL of 70% perchlo-
ric acid, 12 mL of ddH2O) was added to each tube and
mixed. Tubes were incubated at 65°C for 15 minutes.
Absorbance was measured against a blank at 550 nm.
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in Cultured Rat Dermal Fibroblasts
Cells were plated at 7 105 cells/well in six-well plates in
complete growth medium (DMEM plus 10% FCS; Gibco/
BRL). Cell monolayers were scraped twice in perpendic-
ular orientations with a gel comb producing three 2-mm
scratch wounds. To remove cell debris, cell monolayers
were washed with complete growth medium. Growth me-
dium containing 30 g/mL peptides was added, and cell
cultures were incubated for the indicated times at 37°C
and 5% CO2. Cells were lysed in 250 mL of radioimmu-
noprecipitation assay buffer containing 1:100 diluted pro-
teinase inhibitor cocktail (Sigma). Protein concentration
was determined by Lowry protein assay kit (Cytoskeleton,
Denver, CO) following the manufacturer’s instructions.
Twenty micrograms of protein was resolved over an 8%
SDS-PAGE gel followed by protein transfer to a nitrocel-
lulose membrane. Nitrocellulose membranes were incu-
bated for 1 hour at room temperature in 5% skim milk/
Tris-buffered saline/0.1% NP-40 to block nonspecific
protein binding sites. Membranes were then incubated
overnight at 4°C with Tris-buffered saline/1% skim milk/
0.1% NP-40 containing 1:250 diluted collagen I Ab. Next,
membranes were washed with Tris-buffered saline/0.1%
NP-40 15 minutes at room temperature followed by a
30-minute incubation with 1:4000 diluted horseradish
peroxidase–coupled anti-rabbit secondary Ab. Next,
membranes were washed three times 15 minutes with
Tris-buffered saline/0.1% NP-40 at room temperature fol-
lowed by protein detection with ECL Plus kit (Amer-
sham/GE Healthcare) according to the manufacturer’s
instructions.
Collagen Gel Contraction
Collagen 1 gel solution was prepared following the man-
ufacturer’s instructions. In brief, 800 L of ice-cold colla-
gen 1 solution was mixed with 100 L of 0.1 mol/L NaOH
and 100 L of 10 PBS. Four hundred microliters/well of
this mixture was spread on cell culture six-well plates and
allowed to form a gel at 37°C. A total of 25,000 cells/well
were seeded onto the collagen 1 gel. After 24 hours
incubation at 37°C, 5% CO2, collagen gels were released
from the plastic surface using a spatula, and returned to
the incubator. Ten hours later, gels were fixed with 3.7%
paraformaldehyde and the gel area measured by image
analysis using Image J. Primary mouse MEF and rat
dermal fibroblasts were used for these studies.
Time-Lapse Cinemicrography
To quantify random motility, cells were plated at low den-
sity in T-25 cell culture flasks. Cells were serum starved
by culture in defined medium (DMEM, insulin/transferrin,
antibiotics/antimycotics) at 37°C for 24 hours. Cell migra-
tion was stimulated by addition of 10% FCS or Oligo HA
(50 to 500 ng/mL) immediately before filming. Time-lapse
images were acquired every 10 minutes using a
Hamamatsu CCD digital camera (Hamamatsu Photonics,
Hamamatsu City, Japan) attached to a Zeiss Axiovert 100inverted microscope equipped with heated stage. Ran-
dom cell migration was quantified by tracing nuclear
displacement over a 6- to 12-hour period using image
analysis software Northern Exposure 2.9 (Empix Imaging,
Mississauga, ON, Canada).
Microarray Analysis
Subconfluent cultures of RHAMM-transfected (LR21) and
parental 10T1/2 cells were serum starved overnight in
defined culture medium (DMEM, 4 g/mL insulin, 8
g/mL transferrin). This allowed isolation of mRNA that is
modified in expression as a result of RHAMM overexpres-
sion and not the consequence of RHAMM serum or HA
supplements. Total RNA was isolated using TRIzol Re-
agent (Invitrogen) as per the manufacturer’s instructions.
RNA samples were further purified using the QIAgen
RNAeasy kit (Qiagen, Valencia, CA) as per the manufac-
turer’s instructions. After purification, RNA concentration
was determined by absorbance at 260 nm. Three biolog-
ical replicates were used. All gene chips were processed
at the London Regional Genomics Centre (Robarts Re-
search Institute, London, ON, Canada). RNA quality was
assessed using Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA) and the RNA 6000 Nano kit
(Caliper Life Sciences, Hopkinton, MA). Biotinylated com-
plimentary RNA (cRNA) was prepared from 10 g of total
RNA as per the Affymetrix GeneChip Technical Analysis
manual (Affymetrix, Santa Clara, CA). Double-stranded
cDNA was synthesized using SuperScript II (Invitrogen)
and oligo primers. Biotin-labeled cRNA was prepared by
cDNA in vitro transcription using the BioArray High-Yield
RNA Transcript Labeling kit (Enzo Biochem, New York,
NY) incorporating biotinylated UTP and CTP. Labeled
cRNA (10 g) was hybridized to Mouse Genome 430 2.0
GeneChips for 16 hours at 45°C as described in the
Affymetrix Technical Analysis manual (Affymetrix).
GeneChips were stained with streptavidin-phycoerythrin,
followed by an Ab solution and a second streptavidin-
phycoerythrin solution, with all liquid handling performed
by a GeneChip Fluidics Station 450. GeneChips were
scanned with the Affymetrix GeneChip Scanner 3000 (Af-
fymetrix). Signal Intensities for genes were generated
using GCOS1.3 (Affymetrix) using default values for the
Statistical Expression algorithm parameters and a target
signal of 150 for all probe sets and a normalization value
of 1. Gene-level data were generated using the RMA
preprocessor in GeneSpring GX 7.3.1. (Agilent Technol-
ogies). Data were then transformed (measurements less
than 0.01 were set to 0.01) and normalized per chip to the
50th percentile and per gene to control samples. To
determine the effect of RHAMM overexpression on gene
expression, LR21cells were compared to parental 10T1/2
cells. GeneSpring was used to generate fold changes in
gene expression between the two cell lines by applying a
t-test with Bonferroni multiple testing correction with a
significance cutoff of 0.05. The genes with expression
change greater or equal to twofold were considered for
further analysis. Signaling pathways were identified by
Ingenuity Pathway Analysis (Ingenuity Systems, Red-
wood City, CA).
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sion was determined using immunohistochemistry analysis
of P15-1 versus scrambled peptide wounds and microarray
analysis of P15-1–treated subconfluent dermal fibroblasts
versus scrambled peptide–treated fibroblasts. Immunohis-
tochemistry analyses are described above, and microarray
analyses were processed as above. Gene lists were que-
ried with Ingenuity Pathway Analysis, and identification of
signaling/functional networks was used to identify key sig-
naling proteins that are RHAMM/P15-1 regulated.
FAK Signaling
Fibroblasts were cultured to subconfluence (60%), and
then serum starved overnight as described above. Ten-
kDa HA (10 g/mL) was added to cultures, and cells
were lysed 10 to 15 minutes later. FAK was immunopre-
cipitated with anti-FAK Ab (BD Biosciences, Missis-
sauga, ON, Canada), immunoprecipitates were sepa-
rated on SDS-PAGE and transferred to a nitrocellulose
membrane. Immunoprecipitated FAK phosphorylated on
tyrosine was detected using AG10 monoclonal antibody
(Cell Signaling Technology, Danver, MA).
Statistics
Statistical data analysis was performed using Excel soft-
ware (Microsoft). A two-tailed Student’s t-test was used to
assess significance, and P  0.05 was considered sig-
nificant.
Results
RHAMM Binds Preferentially to HA Fragments
and Is Required for HA Fragment–Promoted
Fibroblast Motility
Previous studies suggest that RHAMM binds to HA frag-
ments and that this interaction plays a role in apical
airway microtubule and endothelial cell microfilament-
based motility.27,51 We extended these studies and as-
sessed whether RHAMM also binds to HA fragments/
oligosaccharides when expressed on fibroblasts and
whether this results in increased motility. As shown in
Figure 1A, HA fragments (intermediate, 220 kDa) and
oligosaccharides (10 kDa) both bound to RHAMM from
fibroblast lysates. However, the binding capacity of
RHAMM for HA appeared to be higher for oligosaccha-
rides than intermediate-sized polymers. The effect of
these two HA sizes on fibroblast random motility was
measured (Figure 1B). Both the 220-kDa and 10-kDa HA
stimulated cell motility significantly above negative con-
trol cells receiving only defined medium. Stimulation by
both sizes of HA was similar to that of FCS supplements,
which were used as a positive control in this experiment.
To assess the role of RHAMM in this motility response, the
random motility of RHAMM/ fibroblasts in response to
FCS, 220-kDa HA, and 10-kDa HA was also measured.
As shown in Figure 1B, loss of RHAMM negated a signif-
icant response to both FCS and 10-kDa HA, but not to220-kDa HA. Collectively, these results suggested that
RHAMM preferentially binds to HA oligosaccharides (eg,
10 kDa) and is required for a motogenic response to this
size of HA. Using this information, we next developed an
approach for isolating HA binding peptides that mimic
RHAMM.
Isolation of HA Binding Peptides
HA binding peptides have previously been reported, but
these neither share common sequence patterns nor ex-
hibit strong resemblances to known HA binding sequen-
ces.34–37,52 We developed a combined unbiased/rational
method for identifying HA binding peptides from phage
display libraries using polydisperse HA, which included
the motogenic 220-kDa and 10-kDa polymers as bait.
Phage display libraries were of three different peptide
lengths, which we considered might influence the size of
bound HA (see the flow diagram in Supplemental Figure
S1 at http://ajp.amjpathol.org). To identify phage display
peptides that bind to HA and not to the Sepharose back-
ing, a step in the isolation procedures was included in
which binding of peptides to HA beads was competed by
an excess of unlabeled, 10-kDa HA (10 mg/mL) (see
Supplemental Figure S1 at http://ajp.amjpathol.org). HA
binding phage, which also bound to CS-Sepharose, were
discarded. Phage display peptide sequences were aligned
using BLAST programs53 to determine their relatedness to
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Figure 1. A motogenic response to HA fragments requires RHAMM. A:
RHAMM binds to 220-kDa and 10-kDa HA. Lysates from RHAMM overex-
pressing mesenchymal cells were incubated with 220-kDa and 10-kDa HA
coupled to Sepharose beads. Proteins bound to beads were resolved on
SDS-PAGE, and RHAMM was detected by Western blot analysis. Arrows
indicate bands that represent full-length RHAMM (RHAMMFL) and a pro-
cessed (truncated) RHAMMTR that is commonly expressed after an injury. B:
Wild-type and RHAMM/MEFs were seeded sparsely on tissue culture plastic
and serum starved in defined medium. Cell migration was stimulated with 10%
FCS (positive control), 220-kDa HA, or 10-kDa HA and quantified by real-time
cinemicrography. Values represent mean  SD of 50 cells. *P  0.001 between
wild-type and RHAMM/ cells, †P  0.001 versus defined medium.each other and also to known HA receptor-binding re-
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oligosaccharides, we focused on characterizing phage
peptide sequences that resembled the protein sequence of
this HA receptor. Peptides that were related to one another
and that also aligned to the HA binding sequence of
RHAMM were synthesized and tested for their ability to
affect response to injury in fibroblast culture assays.
Screening the 7- and 12mer libraries yielded higher
numbers of unique peptide sequences (15 and 14, re-
spectively) than the 15mer library, which resulted in re-
covery of only 2 unique sequences (see Supplemental
Figure S1 at http://ajp.amjpathol.org). Screening of the
7mer library yielded the most sequence heterogeneity:
only 1 sequence of 15 was obtained three times, with the
remaining sequences obtained only once. There were four
groups of sequences isolated from the 12mer library, two of
which were represented only once, whereas the others
were isolated four and seven times, respectively (see Sup-
plemental Figure S1 at http://ajp.amjpathol.org; and data not
shown). Screening the 15mer library resulted in the least
sequence heterogeneity since one sequence was obtained
47 times, whereas the other was isolated 18 times (see
Supplemental Figure S1 at http://ajp.amjpathol.org).
BLAST analyses of HA binding peptides isolated from
the 7- and 12mer libraries showed that they were partially
homologous to one another, often sharing four to five
contiguous amino acids. The 7- and 12mer sequences
contained a high percentage of hydrophobic residues
(50% to 70%) in comparison to the residues of 15mer
peptides (35%), in this way resembling a previously
reported 12mer peptide (Pep-1).38 Only 1 of 15 7mer and
3 of 14 12mer peptides aligned to the HA binding region
of RHAMM, but these exhibited very low overall homology
to this protein (eg, 25%, data not shown). By contrast,
the two 15mer HA binding sequences, which were similar
to one another, both aligned to the HA binding region of
RHAMM with a sequence homology of 67% (most frequent
sequence) and 33%, respectively. Furthermore, the most
frequently isolated clone, STMMSRSHKTRSHHV (desig-
nated peptide 15-1), aligned to a sequence within the
RHAMM HA binding region that contains basic amino
acids essential for binding to HA and that form a BX7B
motif59 (see Supplemental Figure S1 at http://ajp.amj-
pathol.org). None of the peptides aligned within the HA
binding region of either CD44 or LYVE-1, and none
showed significant alignment (eg, 25%) to TLR2 or
TLR4 protein sequence. These results suggested that the
size of peptide influenced selection of peptides that re-
semble biological HA receptors. HA binding phage pep-
tides isolated from the 7-, 12-, and 15mer libraries were
synthesized and tested for their ability to inhibit HA-stim-
ulated fibroblast migration.
Peptide 15-1 Reduces HA-Dependent
Fibroblast Migration in a Dose-Dependent
Manner, and This Effect Requires RHAMM
Expression
The effect of the above HA binding peptides on fibroblast
migration was measured using scratch wound tests. Apreviously isolated 12mer, HA binding peptide Pep-1,
was also included in this screen since it blocked migra-
tion of Langerhan’s cells,38 reduced experimental metas-
tases of melanoma cells,60 and decreased focal contacts
of squamous esophageal carcinoma cells.61 Most HA
binding peptides had a slight inhibitory or stimulatory
effect on fibroblast migration responding to FCS in
scratch wound assays (data not shown). However, P15-1
caused the largest significant decrease in fibroblast mi-
gration (data not shown). We therefore selected this pep-
tide for further characterization. A dose-response analy-
sis showed that P15-1 inhibited random fibroblast motility
in a concentration-dependent manner between 0.1 and
10 g/mL, reaching a maximum inhibition when added to
subconfluent cells at 10 g/mL (see Supplemental Figure
S2A at http://ajp.amjpathol.org).
To verify that P15-1 blocked HA oligosaccharide-de-
pendent migration of rat dermal fibroblasts, the effect of
P15-1 and its scrambled counterpart, used as a negative
control, were added to scratch-wounded fibroblast
monolayers (Figure 2A). HA oligosaccharides (500 ng/
mL, 10-kDa polydisperse mixture) or purified 4-, 6-, and
30-monosaccharide HA oligosaccharides (4-, 6-, 30-mer
HA) were added together with either P15-1 or scrambled
peptide (10 g/mL) at the time the monolayers were
wounded. A similar stimulation of migration was obtained
for both the sized 30mer HA oligosaccharides and 10-
kDa polydisperse mixture (Figure 2A shows stimulation
with 30mer HA), but 4- and 6mer oligosaccharides were
not stimulatory in this assay (data not shown). These
results indicated that P15-1 prevented dermal fibroblast
migration in response to the 30mer HA, whereas the
scrambled peptide did not. The blocking ability of P15-1
peptide was similar to a function-blocking anti-RHAMM
Ab (Figure 2B).
We next assessed whether the ability of P15-1 to block
motility in response to 30mer or 10-kDa (polydisperse
mixture) HA required expression of RHAMM or CD44.
Wild-type, CD44/, and RHAMM/ MEF were used for
these experiments.39 The migration of both wild-type
MEF, which expressed both CD44 and RHAMM, and
CD44/ MEF, which expressed RHAMM, into scratch
wounds was blocked by P15-1, but not by scrambled
P15-1 sequence (Figure 2C). By contrast, the migration of
RHAMM/ MEF was unaffected by P15-1 (Figure 2C).
These results suggested that P15-1 reduced dermal fi-
broblast migration by mimicking RHAMM HA binding se-
quences and competitively blocking HA fragment/
RHAMM interactions. To directly demonstrate this ability
of P15-1, we assessed the degree to which it blocks
recombinant RHAMM:HA interactions.
Peptide 15-1 Binds Directly to 10-kDa HA
Oligosaccharides and Competes with Their
Binding to Recombinant RHAMM
We first determined whether we could detect binding of
P15-1 to HA and whether this binding was HA size de-
pendent. We therefore quantified binding of P15-1 to
native HA (MWav  500 kDa) and HA oligosaccharides
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AJP October 2012, Vol. 181, No. 4with MWav 10 kDa, using ITC. The binding curve for the
P15-1 interaction with HA oligosaccharides was sigmoi-
dal and saturable, therefore permitting Scatchard analy-
ses (Figure 3A). Analyses indicated a binding constant
(kDa) of 107 mol/L, an affinity that is approximately six
times higher than the affinity of the previously reported
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Figure 2. P15-1 blocks HA oligosaccharide–induced migration in RHAMM-
expressing fibroblasts. A: Confluent monolayers of rat dermal fibroblasts
were scratch wounded using disposable, plastic Pipetman tips (Gilson,
Middleton, WI). Cells were incubated with culture medium containing 500 ng
of HA oligosaccharides (10 kDa, sized 30mer HA) plus either 50 g/mL P15-1
or scrambled control peptide (Scr Pep). Twenty-four hours later, cell migra-
tion was quantified by counting cells that migrated into the scratch wound.
P15-1 significantly reduces the number of cells that have migrated into the
wound in comparison to scrambled peptide controls. Values represent the
mean  SD of three culture wells. ***P  0.001. B: Confluent monolayers of
RHAMM-expressing MEF were scratch wounded using pipette tips. Cells
were incubated with medium containing anti-RHAMM Ab (30 g/mL), P15-1
(30 g/mL), or Scr Pep (30 g/mL). In the control experiments, cells were
incubated with medium alone. After 11 to 14 hours, cells that migrated into
the scratch wound were counted. P15-1 significantly decreased (***P 
0.001) migration of RHAMM-expressing MEF, and to the same extent as
RHAMM-blocking Ab (*P  0.05). Scrambled control peptide and Isotype-
matched IgG control (IgG) had no effect. Values represent mean  SD of
three culture wells. C: Effect of P15-1 and scrambled control peptide on
scratch wound–induced migration of wild-type, CD44/, and RHAMM/
MEFs. Peptide treatment and cell migration quantification were performed as
described in B. The graph shows that whereas the migration of wild-type and
CD44/ MEF were significantly inhibited by P15-1, it had no effect on
migration of RHAMM/ MEF. Values represent mean  SD of nine culture
wells.12mer HA binding peptide Pep-138 for HA oligosaccha-rides. Interestingly, the kDa of P15-1 for native HA was
106, indicating a much higher affinity of this peptide to
oligosaccharides (data not shown), thus resembling the
preference of RHAMM for oligosaccharides relative to
high molecular weight HA (eg, Figure 1A). ELISA con-
firmed the binding of P15-1 to 10-kDa HA oligosaccha-
rides (Figure 3B). High-performance liquid chromatogra-
phy analysis of this HA, which had been generated by
partial digestion with testicular hyaluronidase, had an
MWav of 10 kDa but was polydisperse in its size distribution,
ranging from 6mers to 40-kDa fragments. We therefore also
assessed the binding of P15-1 to purified, sized 30 HA
monosaccharide species (30mer, approximately 10 kDa)
since P15-1 effectively blocked the ability of this oligosac-
charide to promote fibroblast migration as noted in Figure
2A. ELISA confirmed that P15-1 bound to the 30mer HA
(data not shown). These data suggested that P15-1, like
RHAMM, binds preferentially to HA oligosaccharides.
To determine whether P15-1 competitively blocked
binding of HA oligosaccharides to recombinant RHAMM
protein, we designed ELISA assays to detect displace-
ment of HA fragments from purified recombinant GST-
RHAMM protein, using the polydisperse HA oligosaccha-
ride mixture (10-kDa oligosaccharides) for these assays.
P15-1, but not scrambled peptide, significantly reduced
the binding of HA oligosaccharides to recombinant GST-
RHAMM compared to the PBS control (Figure 3C). Nei-
ther HA nor P15-1 bound to GST alone (data not shown).
HA fragments also bound to recombinant CD44 and
TLR4 protein in these ELISA assays, but P15-1 did not
affect binding to these HA receptors (data not shown).
Higher molecular weight HA (200 kDa) also bound to
recombinant RHAMM in ELISA, but P15-1 was less effec-
tive in reducing binding of this HA size than the above
fragments (data not shown). Collectively, these results
confirmed that P15-1 bound directly to HA and with high-
est affinity to HA oligosaccharides. Results also sug-
gested that P15-1 blocked HA:RHAMM, but not HA:CD44
or HA:TLR4, interactions.
We, and others, have previously shown that RHAMM
expression is required for robust inflammation and fibro-
plasia during repair of adult excisional skin wounds and
that RHAMM function is related to HA fragmentation/oligo-
saccharide production.27,39,51,62,63 We, therefore, chose
this model to assess whether P15-1 blocked HA-induced
cellular functions in vivo. We used excisional skin injury as a
model of acute fibrotic repair in adults64 since, although
loose-skinned animals such as rats do not develop cutane-
ous scars after injury to the extent that tight-skinned animals
do, fibrosis markers including robust inflammation, collagen
I production, fibroplasia, and differentiation into myofibro-
blasts are easily detected in rodent models.64–67
Wound HA Accumulation and Fragmentation
Increases during Repair and Is Maximal
between Days 3 and 7
Fibrogenic repair, which is typical of most adult response-
to-injury processes, is initiated by rapid hemostasis and
consequent release of factors from platelets and serum,
ep (1 
lues rep
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AJP October 2012, Vol. 181, No. 4including hyaluronidase 2,68 which collectively initiate a ro-
bust inflammatory response.1,69,70 This in turn promotes
vigorous fibroplasia and scar formation, particularly in the
deeper dermal regions.71 HA fragments are key regula-
tors of innate immunity and both fibroblast and endothe-
lial migration/proliferation/differentiation,1,4,72 which col-
lectively contribute to wound fibrosis. We first verified that
HA production and fragmentation occurred in excisional
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AJP October 2012, Vol. 181, No. 4tinued to increase at day 3 (D3), reached a maximum at
day 7 (D7), and then began to decrease at day 14 (D14).
Much smaller HA oligosaccharides (eg, 10 kDa) were
evident in day 5 and 7 wounds, which was when RHAMM
expression was maximal.39 Estimates of the total amount
of HA in each identically treated sample showed that the
amount of HA was also highest at day 7 in wounds
treated with scrambled peptide, and in control wounds
treated with PBS/collagen alone, but was relatively con-
stant with time in P15-1–treated wounds (data not
shown). We therefore next determined the consequence
of P15-1 on excisional skin wound repair.
P15-1 Reduces Inflammation, Angiogenesis,
and Fibroplasia/Fibrosis in Excisional Skin
Wounds
Since the hyaluronan fragments accumulating in excisional
wounds were in the MW range of those reported to promote
expression of proinflammatory cytokines bymacrophages,4
we assessed whether P15-1 modified properties of these
cells. Macrophages are a key wound cell type required for
re-establishing tissue integrity and in particular control the
initiation and resolution of the inflammatory phase of tissue
repair.73,74 Their functions vary with each phase of repair
and depend on status of activation, number, differentiation,
and plasticity.75–79 Macrophage depletion from wounds
can therefore have widely differing effects on the course of
repair, depending on the extent to which they are depleted,
the timing of depletion, and whether or not depletion affects
all or subsets of macrophages.
We first assessed whether P15-1 affected macrophage
influx into wounds by quantifying expression of ED-1
mRNA, which provides a sensitive measure of the rat
homolog of CD68 expressed on wound macrophages in
their early stages of differentiation.80 We also measured
Mac3 protein expression since this is a marker for acti-
vated macrophages present in wounds.81 The amount of
ED-1 PCR product was determined following administra-
tion of 0.1 to 100 g/wound site of P15-1 and was stan-
dardized against cellular -actin levels. The reduction of
this standardized ED-1 transcript by P15-1 was pre-
sented as a ratio of the total ED-1 transcript present in
day 1 wounds treated with collagen gel only (Figure 5A).
P15-1 decreased the presence of ED-1–positive macro-
phages in day 1 wounds (Figure 5A), confirming our
previous preliminary demonstration that P15-1 induced
decreased ED-1 protein expression in wounds detected
by immunohistochemistry.82 Further, the decrease in
wound ED-1 mRNA expression was dose dependent,
varying from 40% to 100% inhibition (0.1 to 100 g/
wound site); Mac3 protein expression, which was quan-
tified by counting the number of Mac-3–positive cells per
field in wounds (see Supplemental Figure S2B at http://
ajp.amjpathol.org) was reduced by P15-1 by approxi-
mately 45%. On the basis of these results, we used 30 to
50 g of P15-1 in subsequent experiments to determine
its consequences to repair outcome.
Macrophages recruited to wounds are highly plastic
but have been loosely grouped as proinflammatory (clas-sically activated) or prohealing (alternatively activated)
macrophages.75,83 We next compared the conse-
quences of P15-1 on macrophages polarized to a proin-
flammatory state versus those polarized to a prohealing
state using iNOS84 and Arg1, respectively.85,86 As shown
in Figure 5, B and C, at days 3 and 5, P15-1 strongly
reduced wound iNOS but had little effect on Arg other
than a slight stimulation (P  0.05) of this marker at day
5 after wounding. Representative immunohistochemistry
images of iNOS and Arg1 macrophages are shown in
Supplemental Figure S3 at http://ajp.amjpathol.org). To
identify the predominant proinflammatory pathways that
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Figure 5. Peptide 15-1 reduces macrophage influx into excisional skin
wounds and TGF1 production. A: Full-thickness excisional wounds were
covered with either vehicle alone or vehicle containing different concentra-
tions (100 ng/mL to 100 g/wound site) of P15-1. Wound tissue was isolated
24 hours later. Expression of the macrophage-specific marker ED-1 was
analyzed by PCR. Amplification of -actin transcripts was used as loading
control. Amplification products were separated on an agarose gel. The ED-1
amplification product was quantified by densitometry and corrected for
equal loading by calculating the ratio ED-1:-actin control. P15-1 decreased
the amount of wound ED-1 in a dose-dependent manner. Values are mean
SD. n  3. B: Full-thickness excisional skin wounds were treated with either
P15-1 or scrambled peptide (Scr Pep; 50 g/wound site). Wound sections
were stained with iNos- or Arg1-specific Ab. Positive cells were counted.
P15-1 treatment reduced infiltration of proinflammatory (iNos) macro-
phages into wounds. All graphs represent results of n  3 wounds, five
areas/wound. Values are mean  SD. n  15. *P  0.001. C: Full-thickness
excisional wounds were treated with vehicle alone, P15-1 (50 g/wound
site), or scrambled peptide (50 g/wound site). Day 1 and day 3 wound
sections were stained with TGF1-specific Ab as described in Materials and
Methods. Microscopic images were taken at an original magnification of60,
and TGF1 cells (arrows) were counted. The number of TGF1 cells is
reduced in P15-1–treated wounds at days 1 and 3 after wounding. Graphs
represent mean  SD. n  30. *P  0.01.were blocked by P15-1, we used Proteome Profiler to
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produced by activated macrophages in wounds treated
with P15-1 or the scrambled peptide control (see Sup-
plemental Figure S4 at http://ajp.amjpathol.org). Surpris-
ingly, P15-1 had no detectable effect on the 16 proinflam-
matory cytokines in this profile, which included IL6,
RANTES, and IL1B. Although not conclusive, these re-
sults suggested that P15-1 may have a selective effect on
specific proinflammatory cytokines produced by macro-
phages in early stages of wound repair. Since depleting
early proinflammatory macrophages has previously been
shown to reduce TGF1 production,76 since genetic de-
letion of RHAMM reduces fibroplasia in excisional
wounds,39 and since both HA and RHAMM are required
for TGF signaling,13,87–89 we reasoned that P15-1 treat-
ment might selectively alter wound TGF1 levels. Indeed,
treatment of wounds with P15-1 significantly reduced
TGF1 levels when compared to scrambled peptide con-
trols (Figure 5C).
TGF1 is essential for the phase of repair following
inflammation, called tissue formation, which involves fi-
brogenesis, neovascularization, and transient scar for-
mation typified by increased collagen production and
appearance of myofibroblasts.90–92 Selective reduction
of macrophages during the inflammation stage of wound
repair results in modification of processes characteristic
of the tissue formation phase, in particular, reducing
wound TGF1, fibrogenesis, neovascularization, myofi-
broblast differentiation, and contraction. By contrast, de-
pletion of macrophages during the tissue formation stage
of wound repair has much more serious consequences to
repair and results in severe hemorrhage as well as lack of
wound maturation and closure.76 Based on our results
showing a reduction in proinflammatory macrophages
and wound TGF1 levels, we predicted that processes
occurring during the tissue formation phase of wound
repair might be most strongly affected by P15-1.
By day 7 in collagen gel alone or scrambled peptide–
treated control wounds, re-epithelialization was almost
complete, the clot was intact, and fibroblasts as well as
endothelial cells had migrated into the granulation tissue
so that both fibroplasia and angiogenesis were abun-
dant, as shown by wound cross sections stained with
Masson’s trichrome (see Supplemental Figure S5 at
http://ajp.amjpathol.org, and Figure 6). Both the density of
fibroblasts and blood vessels was significantly reduced
by P15-1 treatment compared to wounds treated with
collagen gels alone (Figure 6; see also Supplemental
Figure S5 at http://ajp.amjpathol.org) or scrambled pep-
tide controls (data not shown), whereas re-epithelializa-
tion appeared to be enhanced (Supplemental Figure S5
at http://ajp.amjpathol.org, and data not shown). Higher
magnification images clearly showed reduced fibroblast
and blood vessel density resulting from P15-1 treatment
(Figure 6A). As expected by the blunted fibroplasia,
wound collagen was also significantly decreased by
P15-1 as measured by wound hydroxylproline content at
day 7 (Figure 7A), PCR of collagen I mRNA of day 1
wounds (Figure 7B), and image analysis of Masson’s
trichrome staining (see Supplemental Figure S5 at http://
ajp.amjpathol.org). To determine whether the effect ofP15-1 on wound collagen production was a direct effect
like its antimigration properties or an indirect conse-
quence of dampened inflammation, we repeated these
experiments using rat dermal fibroblasts in culture. P15-1
or scrambled peptide was added to fibroblast monolay-
ers that had received multiple scratch wounds, and col-
lagen I expression was detected at various times after
wounding using Western blot analyses. -actin was used
as a loading control (Figure 8B). As shown in Figure 8A,
P15-1 strongly reduced collagen I expression 24, 72, and
96 hours after wounding. These results suggested that
P15-1 directly inhibits collagen I production in dermal
fibroblasts. We next assessed the consequences of
P15-1 on wound myofibroblast differentiation in vivo using
smooth muscle actin as a marker, as shown in Figure 9,
A and B. P15-1 reduced the expression of smooth muscle
actin in day 5 wounds. Consistent with this observation,
P15-1 also significantly reduced wound contraction at
day 5 post injury compared to untreated or scrambled
peptide–treated control wounds. To determine whether
these effects of P15-1 on wound contraction were direct
or indirect, peptide was added to collagen lattice con-
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Figure 6. Peptide 15-1 reduces fibroblast density and blood vessel density in
granulation tissue. A: Full-thickness day 7 excisional wounds were treated
with collagen vehicle alone (PBS control), scrambled peptide in collagen
vehicle (image not shown), or P15-1 in collagen vehicle (P15-1, 50 g/
wound site). Cross sections of day 7 wounds were stained with Masson’s
trichrome, allowing differentiation of collagen (blue), muscle, and cells.71
Angiogenesis and fibrogenesis was reduced in P15-1–treated wounds at day
7. B: Granulation tissue fibroblasts and blood vessels were counted in wound
sections. P15-1 significantly decreased the numbers of fibroblasts and blood
vessels in granulation tissue (day 7) compared to both PBS and scrambled
peptide (scr pep) controls. The effects of scrambled peptide on fibroblasts
and blood vessels were not significantly different from vehicle control.
Graphs represent the mean  SD. n  6 wounds. *P  0.001.traction assays imbedded with dermal fibroblasts. As
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AJP October 2012, Vol. 181, No. 4shown in Figure 9C, P15-1 significantly inhibited collagen
lattice contraction, showing that P15-1 has the potential
to directly modulate myofibroblast activity in addition to
fibroblast collagen production. TGF1 regulates expres-
sion of tenascin C, a matricellular protein, which like
RHAMM is expressed in postnatal tissue only in wounds
or disease.93,94 Tenascin C plays a complex role in
wound remodeling and, for example, can both enhance
and limit dermal fibroblast migration.95 High tenascin ex-
pression in rodent skin is associated with modified adult
skin repair, in particular a reduction in wound scarring
and an increase in regenerative healing.93,96 Since P15-1
reduced markers associated with fibrosis/scarring and
since genetic deletion of RHAMMmodified wound tenascin
C expression,39 we assessed whether this peptide altered
wound tenascin C expression. As shown in Figure 10, P15-1
significantly increased tenascin C expression at day 5 but
had no effect at the other time points.
P15-1 did not appear to delay wound resolution in
terms of resolution of granulation tissue, fibrogenesis or
re-appearance of normal skin architecture (data not
shown). Therefore, our collective results suggested that
P15-1 was dampening “fibrosis” and transient scar for-
mation during the tissue formation phase of skin wound
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was isolated 24 hours after wounding, and collagen I transcripts were am-
plified by RT PCR. Amplification of -actin transcripts was used as loading
control. Amplification products were separated on an agarose gel and quan-
tified by densitometry. The collagen I amplification products were corrected
for equal loading by calculating the ratio collagen I/-actin control. Collagen
I expression in control wounds were set to one. P15-1 decreased collagen I
mRNA expression 24 hours after wounding. The values represent typical
results that were replicated three separate times.repair partly as a result of a selective effect of P15-1 onproinflammatory macrophage function, in particular pro-
duction of wound TGF1 and partly by direct blocking of
RHAMM function in fibroblasts.
P15-1 Does Not Alter Excisional Skin Wound
Repair of RHAMM/ Mice
Our data showing that P15-1 exhibited sequence homol-
ogy with RHAMM HA binding regions, blocked the bind-
ing of HA oligosaccharides to recombinant RHAMM,
blocked migration of RHAMM-expressing, but not
RHAMM/, fibroblasts and had similar effects on exci-
sional skin wound properties to RHAMM loss, suggested
that P15-1 acted as a RHAMM peptide mimic. To more
conclusively assess this possibility, we compared the
effects of P15-1 on excisional skin wounds of wild-type
and RHAMM/ mice. We reasoned that if P15-1 acts as
a specific RHAMM antagonist (eg, RHAMM mimetic pep-
tide), we would observe an effect of the peptide on wild-
type, but not RHAMM/, wounds. Since we showed that
P15-1 had an easily measured effect on the production of
TGF1 and tenascin C accumulation in wounds, we ex-
amined the effects of P15-1 on these properties. As
shown in Figure 11A, P15-1 significantly reduced TGF1
staining in wild-type wounds. As expected from the
blunted fibrosis/fibrogenesis of RHAMM/ wounds,
TGF1 staining was less than in wild-type wounds. Nev-
ertheless, P15-1 treatment did not significantly alter levels
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AJP October 2012, Vol. 181, No. 4of this cytokine in RHAMM/ wounds compared to
scrambled peptide controls. We have previously re-
ported that wound tenascin C protein levels are in-
creased in RHAMM/ relative to wild-type wounds.39
Here, we show that P15-1 similarly increased tenascin C
expression in wild-type wounds but had no such detect-
able effect on RHAMM/ wounds (Figure 11B). Collec-
tively, these results provided strong evidence that P15-1
behaves as a RHAMM peptide mimetic and likely blocks
HA:RHAMM signaling through a competitive antagonism.
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Figure 10. Peptide 15-1 increases wound tenascin C protein. Full-thickness
excisional wounds were covered with collagen vehicle alone (image not
shown), P15-1 in collagen gel (50 g/wound site), or scrambled control
peptide in collagen gel (50 g/wound site). Sections were stained with
tenascin C–specific Ab as described in Materials and Methods. Microscopic
images were taken, and tenascin C staining intensity was quantified by image
analysis using Image J. P15-1 increased tenascin C protein expression in
wounds at day 5 after injury. Graphs represent the mean  SD. n  6
wounds. *P  0.001.P15-1 Blocks a RHAMM Signal Guiding
Differentiation of Myofibroblasts
To further dissect the molecular mechanisms by which
P15-1 affected wound fibrosis, we used microarray anal-
yses to assess the consequences of RHAMM overex-
pression and P15-1 inhibition on gene expression. We
used cultured fibroblasts for these studies because we
showed here that P15-1 acted directly on fibroblasts by a
RHAMM-mediated mechanism. We analyzed the conse-
quences of RHAMM overexpression in MEF in serum-free
medium as described in Materials and Methods to isolate
the effect of elevating the expression of this gene from
growth factor effects. The consequences of P15-1 on
mRNA expression of cultured RHAMM expressing MEF
responding to wound injuries were also analyzed. The
relationship of genes that were altered as a consequence
of both RHAMM expression and P15-1 exposure
(see Supplemental Table S1 at http://ajp.amjpathol.org)
were probed using Ingenuity Pathway Analysis. As
shown in Figure 12A, pathway analysis identified a func-
tional network that affected dermal, connective tissue,
and inflammatory diseases and that featured a canonical
FAK signaling pathway. Pathway components of this net-
work are important genes controlling myofibroblast differ-
entiation and include RHAMM/HMMR, TGF1, smooth
muscle actin (acta 2), tenascin C (Tnc), and collagen I
(Col1).97 Since the results of these unbiased analyses are
consistent with our evidence that P15-1 appears to block
fibroblast/myofibroblast differentiation, we determined
whether P15-1 alters FAK tyrosine phosphorylation status,
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AJP October 2012, Vol. 181, No. 4activity of this kinase. We, and others, have previously
shown that FAK undergoes cycles of phosphorylation/de-
phosphorylation that are required for focal adhesion turn-
over and appropriate dynamic timing of signaling.98–102
Our results showed that P15-1 promoted hypertyrosine
phosphorylation of FAK in comparison to treatment with
HA oligosaccharides alone, and thus, P15-1 has the po-
tential of disrupting appropriate signaling through FAK
(Figure 12B). These results are similar to previous evi-
dence showing that FAK activity is required for TGF1-
induced myofibroblast differentiation,103–106 that block-
ing the HA binding ability of RHAMM results in both loss
of cell migration and an increase in phosphorylation of
FAK on tyrosine,102 and that blocking Ras-regulated
pathways via HA oligosaccharide promoted ERK1,2
activity26 results in hyperphosphorylation of FAK and
consequent inhibition of cellular functions such as mi-
gration and differentiation.107–109 Collectively, our re-
sults suggested that P15-1 directly modifies the myo-
fibroblast phenotype in excisional skin wounds as
depicted in the model (Figure 12C).
Discussion
HA deposition is transiently increased following acute
response to injury of most tissues1,5,72,98,110,111 and per-
forms complex and molecular weight–dependent func-
tions during repair. High molecular weight or native HA is
present in all layers of uninjured skin and is, as we have
confirmed here, increased following excisional injury in a
time-dependent manner. High molecular weight HA (eg,
500 kDa) performs a number of functions during repair
including promoting keratinocyte migration, regulating tis-
sue edema, suppressing vascularization and inflammation,
and controlling myofibroblast differentiation.112–114 Follow-
ing tissue injury, both oxygen free radicals generated by
injury and hyaluronidases released by pathogens and
hemostatic events (eg, platelet aggregation) at the
wound site degrade HA to produce fragments (eg, 50 to
400 kDa) and oligosaccharides (ca. 25 kDa). Interme-
diate HA fragments (50 to 400 kDa) stimulate keratino-
cyte activation and proliferation, as well as fibroblast pro-
Day 3 Wildtype acve scr  pepde Day 3 Wildtype P-15 pepde 
Day 3 RHAMM-/- scr pepde Day 3 RHAMM-/- P-15 pepde
100 µm
A
0
10
20
30
40
50
60
70
80
90
100
*
# 
of
 c
el
ls
/ﬁ
el
d
Figure 11. P15-1 does not affect TGF1 or tenascin C levels in RHAMM/
mice were treated with collagen vehicle plus either P15-1 or scrambled contr
The graph depicts the number of positively stained cells per microscopic fi
tenascin C–specific Ab. A representative image of n  4 is shown.liferation observed during repair, act as innate alloimmuneagonists, promote neoangiogenesis, control inflammatory
cascades, and also contribute to myofibroblast differentia-
tion.1,4,72 HA oligosaccharides (eg, 10 kDa) may perform
dual roles during repair and disease processes because,
on the one hand, they promote fibroblast migration/prolifer-
ation, angiogenesis, and increased expression of wound
proinflammatory cytokines,1,3,26 but on the other hand, can
block HA/HA receptor interactions that promote survival
pathways.2 Collectively, these results suggest that a com-
plex interplay exists amongst high molecular weight, inter-
mediate molecular weight, and small HA oligosaccharides,
which collectively regulate wound repair and resolution.
These same HA MW forms appear to play key roles in
disease initiation and progression, in particular those dis-
eases in which chronic inflammation is involved.1,2,4
Here, we identify a screening process for isolating HA
receptor peptide mimics, which block the activity of low
MW HA. Specifically, we describe isolation of a 15mer
peptide, which acts as a RHAMM peptide mimic: since it
resembles sequences within the HA binding region of
RHAMM, it effectively and selectively competes with re-
combinant RHAMM for HA oligosaccharides, it has sim-
ilar consequences to wound repair as genetic depletion of
RHAMM,39 and requires RHAMM expression to have a
blocking effect. Our results are consistent with previous
reports that RHAMM binds to low molecular weight (eg, 15
to 40 kDa) fragments and oligosaccharides.26,51,63,115,116
Our results suggest that P15-1 may primarily disrupt
the interaction of HA oligosaccharides with RHAMM and
that this particularly affects the inflammatory functions of
proinflammatory macrophages and differentiation of fi-
broblasts into a myofibroblast subtype. Thus, P15-1
binds with higher affinity to a mixture of HA oligosaccha-
rides than to native HA, as detected by ITC. Function
blocking data further suggest that P15-1 may bind to a
specific size range of HA oligosaccharides that are pro-
inflammatory and fibrogenic. For example, although
P15-1 blocks migration in the presence of HA oligosac-
charide mixtures, it maximally affects this cell function in
response to a purified 30-monosaccharide oligosaccha-
ride. However, further studies are required to determine
the precise range of HA fragment and oligosaccharide
Day 5 Wildtype scr pepde Day 5 Wildtype P-15-1 
Day 5 RHAMM-/- scr pepde Day 5 RHAMM-/- P15-1
B
s. A and B: Full-thickness excisional wounds of wild-type and RHAMM/
de. A: Cross sections of day 3 wounds were stained with TGF1-specific Ab.
. n  4. *P  0.001. B: Cross sections of day 5 wounds were stained withwound
ol peptisizes that P15-1 binds to.
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AJP October 2012, Vol. 181, No. 4Our data suggest that the HA oligosaccharide:RHAMM
interactions, which are blocked by P15-1, directly modify
signaling pathways in wound fibroblasts and thus alter
myofibroblast differentiation. Thus, we show that RHAMM
and P15-1 regulated genes group into a function network
and FAK signaling pathway that is commonly seen in
dermal diseases, connective tissue disorders, and in-
flammatory diseases. The top signaling network is a FAK-
regulated pathway that includes RHAMM (HMMR),
TGF1, ERK1, PDGFBB, Col1, Col 3, Tnc, and Nfkb.
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CRHAMM has previously been linked to PDGFBB func-
tion,117 specifically activates ERK1,42 and is required for
TGF1-promoted fibroblast migration in culture88 and an-
giogenesis via TGFR1/CD44 complexes.89 HA, TGF1,
and FAK97,103–106,118 are now considered to be partners
that coordinate myofibroblast differentiation. The ability of
P15-1 to block myofibroblast differentiation is associated
with the promotion of FAK tyrosine phosphorylation. Li-
gands that activate cell migration/gene expression
through Ras appear to dephosphorylate FAK and facili-
tate turnover of the signaling structures within focal ad-
hesions: reagents that block dephosphorylation of FAK in
this signaling context also block cell migration and focal
adhesion–mediated signaling.107–109 Whether or not
P15-1 directly modifies signaling to affect macrophage
polarization and trafficking into the wounds was not ad-
dressed in this study but remains for future investigation.
A number of reports have described the isolation of
HA binding peptides that range in size from 7- to
12mer,33–36,52,53 and these peptides exhibit biological
activity consistent with their reported HA binding ac-
tivity. Some of these peptides share properties known
to be required for binding to HA, such as clusters of
basic amino acids,34,35,52 and one 12mer exhibits
weak homology with TSG-6,53 but they do not exhibit
strong homology with the primary sequence of known
HA binding regions in HA receptors or binding pro-
teins.38 Our studies predict that a 15mer may represent
Figure 12. RHAMM-regulated signaling pathways blocked by P15-1. A:
Protein or mRNA expression of genes, which are subject to regulation by
both RHAMM and P15-1 (see Materials and Methods), were identified by
performing immunohistochemistry of wound beds or microarray analysis of
RHAMM transfected versus parental fibroblasts, and P15-1–treated versus
scrambled peptide–treated RHAMM-expressing fibroblasts. Genes that were
altered in their expression by P15-1 (but not by negative controls), as well as
by RHAMM transfection, were identified and analyzed for functional net-
works/canonical signaling pathways using Ingenuity Pathway Analysis (In-
genuity Systems, Redwood City, CA). Analyses identified the top functional
network (shown in A) as one associated with connective tissue disorders,
dermatological diseases, and inflammation. The most significant molecular
and cellular functions predicted by these associations included cell cycle
(P  3.7  107) and cell-to-cell signaling and interaction (P  3.9  107).
The top canonical signaling pathway was FAK (focal adhesion kinase) sig-
naling (P  2.5  107) as shown in A. Genes that have previously been
linked to RHAMM (red box, identified as HMMR) are marked in orange, and
those that have been shown to be directly or indirectly modified through an
action on signaling pathways are marked in solid (direct) or dashed (indirect)
red lines. Genes identified in the present study to be regulated by RHAMM
and P15-1 on the FAK signaling pathway are pink, and their relationships to
each other are indicated by solid or dashed pink lines. B: Based on the
analysis in A, the consequence of P15-1 on FAK tyrosine phosphorylation
status was assessed following exposure to HA oligosaccharides (10 kDa) as
described in Materials and Methods. The control, scrambled peptide, re-
sulted in light phosphorylation of FAK, whereas by contrast, P15-1 treatment
strongly and significantly increased FAK phosphorylation at all doses tested
(P  0.001). This was sustained over time and was associated with inability
of focal adhesions, which contain large signaling complexes linked to the
microenvironment, to turnover and signal appropriately (data not shown). C:
Literature searches of the FAK pathway shown in A regulate myofibroblast
differentiation within wounds (see Discussion). The consequences of
RHAMM, HA oligosaccharides and blocking of these interactions by P15-1 are
modeled in C. HA oligosaccharides bind to cell surface RHAMM, which in
turn regulates signaling in focal adhesions through FAK, thus contributing to
myofibroblast differentiation/migration. P15-1 is proposed to compete for
RHAMM in binding to HA oligosaccharides thus blocking appropriate
RHAMM signaling through FAK/ERK1. This aberrant signaling block by P15-1
results in a downstream decrease in Tgf1, Acta2, Col1, and Col3 expression
and an increase in Tnc expression with a consequent loss of myofibroblast
phenotype.myoﬁbroblast diﬀerenaon 
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receptor peptide mimics with homology to small HA
binding regions such as RHAMM. We also predict that
larger peptides or multimers of peptides will be re-
quired for competitively dislodging HA from the bigger
HA binding groove of proteins with link module-like HA
binding regions, such as CD44.
Aberrant wound repair is an increasing burden on health
care due to the aging population and rise of obesity-related
diseases such as diabetes.119 Both chronic wounds and
fibrotic repair of wounds cause significant morbidity and
mortality within these patient groups.69,120–122 Chronic
wounds and excessive scarring of wounds are both driven
by prolonged inflammation, which affects the proliferative
and remodeling phases of the response-to-injury pro-
cess.69,73,111,123,124 Considerable evidence using trans-
genic mouse models supports an essential role for mac-
rophages in acute wound repair of adult tissues.64,65
Macrophages release factors that affect keratinocytes,
endothelial cells, and fibroblasts. For example, depletion
of macrophages from the inflammatory stage of tissue
response to injury results in reduced granulation tissue
formation, scarring, and compromised re-epithelialization
of the wound. The depletion of macrophages mid-repair
during tissue granulation tissue formation results in se-
vere vascular defects and hemorrhaging of the wound. In
both instances, wounds do not complete remodeling and
do not close completely.76,77 By contrast, the role of
dermal fibroblasts, which are clearly a heterogeneous
cell population of papillary, reticular fibroblasts, fibro-
cytes, and pericytes, in excisional wound repair is not yet
as well understood.
HA and at least two of its receptors, CD44 and
RHAMM, are known to regulate immunity during tissue
repair,1,4,16,125–127 in particular, innate immune cells
such as macrophages, and fibrogenesis. Loss of CD44
results in prolonged macrophage infiltration into bleomy-
cin-injured lung tissue, and persistence/activation of this
cell type is considered to be largely responsible for the
unremitting inflammation and subsequent tissue destruc-
tion following tissue injury.4 Our previous results show
that genetic deletion of RHAMM also disrupts signals
coordinating innate immunity and fibrogenesis. For ex-
ample, excisional wounds of RHAMM/ mouse skin ex-
hibit prolonged neutrophil survival but reduced macro-
phage accumulation.39 Wounds of such mice also exhibit
reduced fibroplasia and aberrant mesenchymal differen-
tiation. Our collective evidence, particularly the lack of
P15-1 effect on RHAMM/ wounds, indicate P15-1 is a
RHAMM mimic. Our results further predict that the con-
sequence of RHAMM loss on inflammation and fibropla-
sia results, at least in part, from aberrant HA oligosac-
charide signaling.
Although interventions that promote wound repair have
been known for centuries, these are largely devoid of
drug-based therapies, and promoting wound repair to
resolve ulcers and reduce fibrotic repair to attenuate
scarring continue to be major clinical problems. Drugs
that affect sensitivity to the TGF family of fibrotic cyto-
kines are in phase I and II clinical trials, and blocking
CX43 function/expression is in the pre-clinical phase ofassessment for treatment of chronic and fibrotic
wounds.93,119 Clearly, there is need for additional targets
that can on the one hand reduce tissue fibrosis and on
the other hand promote a regenerative mechanism dur-
ing normal and pathological wound repair. Our results
suggest that targeting the interactions between HA and
cell receptors, which blunt inflammation and fibrogenesis
via an effect on FAK signaling, is a feasible method for
fine tuning the extent of fibrosis versus regeneration
within acute wounds.
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